^
    1d
    Lisatoclax Plus R-CHOP or Pola-R-CHP in Untreated DLBCL: A Phase Ib/II Study (clinicaltrials.gov)
    P1/2, N=122, Not yet recruiting, Sun Yat-sen University
    New P1/2 trial
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • lisaftoclax (APG-2575) • Polivy (polatuzumab vedotin-piiq)
    1d
    A Phase 1b/2 Multisite Dose-finding and Expansion Study of WTX-330 in Adult Patients With Selected Advanced or Metastatic Solid Tumors or Lymphoma (clinicaltrials.gov)
    P1/2, N=100, Active, not recruiting, Werewolf Therapeutics, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    WTX-330
    1d
    Electronic Health Mindfulness-based Music Therapy Intervention for Patients Undergoing Allogeneic Stem Cell Transplantation (clinicaltrials.gov)
    P=N/A, N=60, Active, not recruiting, University of Miami | Trial completion date: Dec 2025 --> Jun 2026
    Trial completion date
    1d
    ARV-393-101: A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma. (clinicaltrials.gov)
    P1, N=255, Recruiting, Arvinas Inc. | N=112 --> 255 | Trial completion date: Dec 2025 --> Mar 2028 | Trial primary completion date: Dec 2025 --> Mar 2028
    Enrollment change • Trial completion date • Trial primary completion date • First-in-human
    |
    Columvi (glofitamab-gxbm)
    2d
    Copanlisib With Ibrutinib for Patients With Recurrent/ Refractory Primary Central Nervous System Lymphoma (PCNSL) (clinicaltrials.gov)
    P1/2, N=18, Completed, Memorial Sloan Kettering Cancer Center | Active, not recruiting --> Completed | Trial completion date: Jul 2026 --> Feb 2026 | Trial primary completion date: Jul 2026 --> Feb 2026
    Trial completion • Trial completion date • Trial primary completion date
    |
    Imbruvica (ibrutinib) • Aliqopa (copanlisib)
    2d
    CRP Regimen in Treating Elderly Patients With Previously Untreated Double-Positive DLBCL (clinicaltrials.gov)
    P2, N=58, Recruiting, Tianjin Medical University Cancer Institute and Hospital
    New P2 trial
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    Rituxan (rituximab) • Epidaza (chidamide) • Polivy (polatuzumab vedotin-piiq)
    2d
    Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas (clinicaltrials.gov)
    P2, N=49, Recruiting, Emory University | Trial completion date: Jan 2026 --> Jan 2027 | Trial primary completion date: Sep 2025 --> Sep 2026
    Trial completion date • Trial primary completion date
    |
    Gazyva (obinutuzumab) • Calquence (acalabrutinib)
    2d
    SJFAMILY: Familial Investigations of Childhood Cancer Predisposition (clinicaltrials.gov)
    P=N/A, N=1500, Recruiting, St. Jude Children's Research Hospital | N=3000 --> 1500
    Enrollment change
    2d
    LS1781: Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia (clinicaltrials.gov)
    P2, N=80, Recruiting, Mayo Clinic | Trial completion date: Nov 2033 --> Mar 2027 | Trial primary completion date: Feb 2031 --> Mar 2027
    Trial completion date • Trial primary completion date
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • BCL2 (B-cell CLL/lymphoma 2) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • DNMT3A (DNA methyltransferase 1) • SF3B1 (Splicing Factor 3b Subunit 1) • TET2 (Tet Methylcytosine Dioxygenase 2) • SRSF2 (Serine and arginine rich splicing factor 2) • U2AF1 (U2 Small Nuclear RNA Auxiliary Factor 1) • CD4 (CD4 Molecule) • ZRSR2 (Zinc Finger CCCH-Type, RNA Binding Motif And Serine/Arginine Rich 2)
    |
    IDH2 mutation • TET2 mutation • SF3B1 mutation • EZH2 mutation • SRSF2 mutation
    |
    cisplatin • carboplatin • gemcitabine • Rituxan (rituximab) • cytarabine • cyclophosphamide • ifosfamide • oxaliplatin • etoposide IV • decitabine • Truxima (rituximab-abbs) • Hemady (dexamethasone tablets) • Mabtas (rituximab biosimilar) • Starasid (cytarabine ocfosfate) • dexamethasone injection
    2d
    Acalabrutinib With or Without Obinutuzumab in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (clinicaltrials.gov)
    P2, N=120, Recruiting, Mayo Clinic | Trial primary completion date: Oct 2030 --> Mar 2027
    Trial primary completion date
    |
    CD20 (Membrane Spanning 4-Domains A1) • CCND1 (Cyclin D1) • CD5 (CD5 Molecule) • FCER2 (Fc Fragment Of IgE Receptor II)
    |
    Chr t(11;14)
    |
    Gazyva (obinutuzumab) • Calquence (acalabrutinib)
    2d
    A Study to Evaluate the Tolerability, Safety, and Efficacy of an Anti-CD19 CAR-T Product in Patients With B-cell Lymphoproliferative Disorders (clinicaltrials.gov)
    P1/2, N=58, Completed, National Research Center for Hematology, Russia | Recruiting --> Completed | Trial completion date: Mar 2026 --> Nov 2025
    Trial completion • Trial completion date • IO biomarker
    |
    TP53 (Tumor protein P53) • MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • CD19 (CD19 Molecule) • BCL6 (B-cell CLL/lymphoma 6)
    |
    TP53 mutation